PURPOSE: To assess the efficacy of recombinant human growth hormone (rhGH), testosterone, and anabolic steroids in the treatment of HIV wasting. METHODS: A systematic review and meta-analysis of studies published in English since 1996 was conducted. Studies of anabolic steroids, testosterone, and rhGH in treatment of HIV wasting reporting the efficacy outcomes of body composition measures, work output, or health-related quality of life (QoL) were eligible. Meta-analyses were performed for mean pre-post change in lean body mass (LBM), the within-study mean difference in pre-post change for LBM, and of odds ratios for certain safety events. RESULTS: A total of 18 studies met inclusion criteria for this review. CONCLUSION: The 3 treatments for HIV wasting assessed--rhGH, testosterone, and anabolic steroids--all demonstrated significant efficacy in increasing LBM as compared with placebo. Although meta-analysis did not indicate any statistically significant differences between these agents in the degree of efficacy in this outcome, the Food and Drug Administration-approved dose of rhGH may have advantages over the other 2 therapies in terms of improvements in functional capacity and QoL.
PURPOSE: To assess the efficacy of recombinant humangrowth hormone (rhGH), testosterone, and anabolic steroids in the treatment of HIV wasting. METHODS: A systematic review and meta-analysis of studies published in English since 1996 was conducted. Studies of anabolic steroids, testosterone, and rhGH in treatment of HIV wasting reporting the efficacy outcomes of body composition measures, work output, or health-related quality of life (QoL) were eligible. Meta-analyses were performed for mean pre-post change in lean body mass (LBM), the within-study mean difference in pre-post change for LBM, and of odds ratios for certain safety events. RESULTS: A total of 18 studies met inclusion criteria for this review. CONCLUSION: The 3 treatments for HIV wasting assessed--rhGH, testosterone, and anabolic steroids--all demonstrated significant efficacy in increasing LBM as compared with placebo. Although meta-analysis did not indicate any statistically significant differences between these agents in the degree of efficacy in this outcome, the Food and Drug Administration-approved dose of rhGH may have advantages over the other 2 therapies in terms of improvements in functional capacity and QoL.
Authors: Rakhi Kohli; Robert S Klein; Ellie E Schoenbaum; Kathryn Anastos; Howard Minkoff; Henry S Sacks Journal: J Urban Health Date: 2006-01 Impact factor: 3.671
Authors: Robert D Kersey; Diane L Elliot; Linn Goldberg; Gen Kanayama; James E Leone; Mike Pavlovich; Harrison G Pope Journal: J Athl Train Date: 2012 Sep-Oct Impact factor: 2.860
Authors: Saro H Armenian; Meisi Xiao; Jennifer Berano Teh; Brandyn Lee; Howard A Chang; Kristen Mascarenhas; Sean Lee; Alex Iukuridze; Jack J Xie; Jessica M Scott; Lee W Jones; F Lennie Wong; Stephen J Forman; Ryotaro Nakamura Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: Saro H Armenian; Aleksi Iukuridze; Jennifer Berano Teh; Kristen Mascarenhas; Alex Herrera; Jeannine S McCune; Jasmine M Zain; Sogol Mostoufi-Moab; Shana McCormack; Thomas P Slavin; Jessica M Scott; Lee W Jones; Can-Lan Sun; Stephen J Forman; F Lennie Wong; Ryotaro Nakamura Journal: J Cachexia Sarcopenia Muscle Date: 2020-03-25 Impact factor: 12.910